Clinical Trials Logo

Humoral Rejection clinical trials

View clinical trials related to Humoral Rejection.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01895127 Terminated - Clinical trials for Antibody-mediated Rejection

Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation

Start date: November 2013
Phase: Phase 2
Study type: Interventional

This is an open-label analysis that will compare eculizumab versus Plasmapheresis (PP) and Immunoglobulin (IVIg) for the treatment of antibody-mediated rejection (AMR) in renal transplant recipients. All patients will be evaluated from the time of AMR diagnosis for 12 months.